Introduction
The products of modern biotechnologies -living modified organisms (LMOs) -offer humanitymany potential benefits from the economic, technical, and scientific perspectives. However, in another respect, these LMOs may pose certain risks that could adversely affect human beings and ecosystems, and the concurrent controversies are set to continue. In particular, as LMOs are being utilized by international industries and are thus being transferred from nation to nation, the need has arisen to establish international regulations that will prevent the corresponding potential impact and ensure human safety. Thus, signatories to the Convention on Biological Diversity (CBD) of 1995, in response to these international requirements, prompted the drafting of the Cartagena Protocol on Bio-safety (hereonreferred to as 'the protocol') to deal with the potential risk posed by LMOs. The protocol took effect on September 11, 2003, with the focus placed firmly on the trans-boundary movement of LMOs, and, as of 2005, 126 nations had signed the protocol. Korea signed the protocol in September2000. In order to respond to the demands of civic groups and other organizations to secure bio-safety and lay the groundwork for the implementation of the protocol, the law on the trans-boundary movement of LMOs and other related issues was enacted and promulgated in March 2001 under the impetus of MOCIE. Thereafter, each ministry made efforts to enact the sub-laws and regulations necessary for implementing this law enforcement ordinances to this law were enacted as recently as September 20, 2005 . Korea is spurring the last drive for ratification of the protocol. On September 30, 2005, the nation confirmed the enforcement ordinances of the law on the trans-boundary movement of LMOs, and is progressing to ratification of the protocol, enactment of the enforcement rules, and formulation of notices by related central government agencies. As such, the first half of 2006 will see the enforcement of the protocol and its domestic fulfillment law. Also, the related central government agencies are discussing issues that will arise from the enforcement of the protocol fulfillment law. Following reshaping of the enforcement rules, notices, and other sub-regulations, they are set to present the details on import, production, distribution, handling management, and LMO R&D to the related interests and formulate procedures for enhancing those interests' understanding.
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Trends in Bioethics-related Legislation
The ultimate objective of BT is to diagnose, prevent, and treat human diseases; it must therefore develop in close relationship with humanity. Article 1 of the Law on Bioethics and Safety states, "This law aims to secure bioethics and safety in BT, prevent the infringement of human dignity and values and harm to the human body, and create conditions for developing and using BT for preventing and treating human diseases, thus contributing to the enhancement of national health and life quality." BT research, even from its initial stage, should consider human-related values, risks, benefits, and so forth, as well as examine all the ethical, legal, and social dimensions. Due to this situation, the ethical, legal, and social implications of BT were included in the recent BT research, including research into genomes (ELSI). 
Trends in the BT Intellectual Property System
A. Overview
BT requires long-term R&D investment in order to produce something worthy of patenting, but such patents are easy to steal, and thus the corresponding intellectual property rights should benefit from greater protection. International consensus has been formed in this regard, and, in the long run, the securing of source technologiesand long-term investments towards this end are the sure key to the competitiveness of BT. In Korea, many BT fields are still hovering in the initial, basic stage, and they evidently require intensive R&D investment in accordance with the government's long-term road map. Korea's R&D achievements should be domestically industrialized through powerful patent protection policies. 
B. Status of BT-related Patent Applications -Filing
2004 saw 2,909 cases of BT-related patent applications, up 10.1% from 1998 when they enjoyed an initial surge. With the steady development of the domestic bio-industries, patent applications as filed by nationals account for 62.5%of the total. However, in recent years, the number of filed patent applications has been on the decline, indicating that applicants are pursuing quality rather than quantity Table 1 .
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C. Expansion of Review Infrastructure in BT
KIPO is amending patent review criteria in order to protect new technologies in the rapidly developing BT field, as well as present criteria for bio-ethic standards in line with international trends. According to the BT development trends, KIPO is striving to expand the intellectual property rights system and infrastructure and make patent review professional to protect rights over superior patents efficiently. Please go to KIPO, www. kipo.go.kr for more information.
Current Status and Suggestions for BT Products Approval Procedures
A. Introduction
The level of Korean BT engineering now stands at 80-90% that of the most advanced nations in terms of basic technologies and practicalization technologies, although the nation's bio-industries are more competitive nationally compared with other industries. The problem is that its technologies for assessing the safety and effects of BT products, and approving and permitting them, have yet to equal those of the advanced nations. The enhancement of the mandatory assessment of safety and effects will provide additional impetus to the expansion of Korea's BT medical product sector.
Unlike conventional drugs, bio drugs will involve new materials and new technologies, and as such they can neither enter markets nor obtain reliability in the global market without first ensuring their safety and efficacy. In connection with this matter, the characteristics and authorization processes for biotechnology products, domestic and foreign trends in the development of biomedicine, the influence of biotechnology on the pharmaceutical industry, the KFDA's safety management policy for biotechnology products, and the problems facing the industrialization of biotechnology products, along with any other points concerning the industry, will be reviewed.
B. Domestic Bio Drug Development Trends
To facilitate the commercialization of BT products since 2001, KFDA has implemented the guardian service system, which was designed to provide administrative and technical support from the initial product development stage to the product commercializing stage. Prior counseling is completed or underway for 19 cell therapy products, 13 gene therapy products, 2 DNA chips, and 2 DNA recombinant pharmaceutical products, totaling 37 products from 29 companies. Of these, 3 cell therapy products and 2 DNA chips were approved for market sale.
C. Promotion of Safety Management for BT Products by KFDA
As a complement to the guardian service system run since 2002, if a BT researcher or a BT research institute requests administrative and technical assistance to industrialize and commercialize the research results of a drug, amedical supply, a medical device or a cosmetic product, the KFDA, as of March 2005 and in accordance with the regulations for the operation of the guardian service system for bio drugs and others, will provide the corresponding assistance from the product development stage.
The KFDA has also formulated over 30 guidelines with regard to BT products. The guidelines aim to enhance the reliability of companies engaged the industrialization of cutting-edge BT products, with the aim of preventing unnecessary and duplicate www.asiabiotech.com Biotechnology in Korea Other (2 items) investments. The guidelines also consider the characteristics of those BT products (cell therapy products, gene therapy products, DNA chips, etc.) with a high probabilityof weakening the safety assessment rationalization, since BT products individually have strong proper properties, making it difficult to establish and apply the formatted, common safety and effectiveness-related criteria as is commonly done with general chemical substances and drugs. From 2005 From -2009 , the KFDA will conduct 15 outsourced research projects each year, and formulate safety and efficacy assessment guidelines by product.
In 2003, the KFDA formulated regulationsfor the biological and approval/review systems in consideration of the characteristics of BT products.
BT Companies and Their Support Systems
A. Domestic Trends
A 2004 survey conducted on 605 domestic companies engaged in the bio-industries in 2003 by the Korean Agency for Technology and Standards, the Korea Institute for Industrial Economics and Trade, and the Bio-industry Association of Korea under MOCIE, categorized the companies into two groups: those involved in R&D and product sales (432 respondents), and those involved only in R&D (173 respondents). Of these, 387 were engaged in selling domestic products, 45 were selling imported products, and 41 were selling both domestic and imported products.
Of the 11,013 professionals working in the BT industries, research manpower accounted for 5,808 (53%), 46% of whom were M.S. degree holders, while production manpower numbered 5,205 (47%), with technical manpower accounting for 65%.
B. Scale of the Bio-industries
A survey on the status of the domestic bio-industries in 2003 reported that the total value of supply and demand had been estimated at 2.5923 trillion won. See Table 3 . In terms of supply, production supply stood at 2.0791 trillion won and import supply www.asiabiotech.com Biotechnology in Korea at 513.2 trillion won, while domestic demand accounted for 1.5985 trillion won and export demand 993.8 billion won. In 2004, the estimated total value for supply and demand rose to 3 trillion won. The market value of the domestic bio-industry was worth 1.5985 trillion won in 2003, with domestically-produced products accounting for 1.0853 trillion won (68%) and imported products accounting for 513.2 billion won (32%). See Table 5 . This figure consists of 973.9 billion won (61%) in bio medicines, 357 billion won (22%) in bioprocess devices/bio foods, and 267.6 billion won (17%) for other products. The bio-industry market for 2004 has been estimated at 1.918 trillion won.
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C. Bio-industry Support Systems
In 2004 the government invested 601.6 billion won (with 708.6 billon won projected for 2005) through eight ministries including MOST, MOCIE, and WOHW. See Table 5 .
Under the pan-governmental project for bio drugs and bio organs -selected as a next-generation growth engine -the government is set to inject a subsidy of 35.6 billion won into the bio organ, bio chip, and bio drug sectors in 2005.
Korea's bio-industry support systems are categorized into technology development and infrastructure structuring, and MOST is providing intensive support to five statefunded R&D projects including the Bio Discovery Project, as well as to promising core technologies and next-generation source platform technologies. MOST controls 33% of the government's BT R&D budget. MOCIE is providing support to industrialization technologies development projects including the Bio Star Project, and infrastructure structuring such as the securing of Contract Manufacturing Organizations. MOCIE controls 27% of the government's BT R&D budget.
MOHW is providing support to R&D projects such as healthcare BT development, and infrastructure projects such as infrastructure development for healthcare technologies. MOHW controls 19% of the government's entire BT R&D budget.
Furthermore, five ministries -MAF, MOE & HRD, MIC, MOE, and MOMAF -support their respective R&D projects, controlling 21% of the government's BT R&D budget.
In addition to this overall support, the related ministries and agencies are providing support for bio-industry-related facility fund loans, business incubation, and business fostering aimed at facilitating the development of the bio-industries, and they are also committed to activating related companies through regional BT cluster formation and support for international cooperation. 
